🔗 Share this article

The first new treatments for gonorrhoea in a generation are being described as a "huge turning point" in the battle against drug-resistant strains of the pathogen, according to researchers.

An International Health Concern

The sexually transmitted infection are increasing worldwide, with data suggesting in excess of 82 million infections annually. Particularly high rates are seen in Africa and nations within the WHO's Western Pacific region, which includes Mongolia and China to New Zealand. Across England, cases have hit a record high, while rates across Europe in 2023 were triple the level compared to the rates from 2014.

“The clearance of novel therapies for gonorrhoea is an important and timely step in the face of rising global incidence, the spread of superbugs and the highly restricted treatment choices presently on offer.”

Public health authorities are particularly alarmed about the increase in treatment-resistant strains. The global health body has designated it as a "priority pathogen". A tracking program showed that resistance to key first-line drugs like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Two New Therapies Secure Approval

One new antibiotic, also known as Nuzolvence, was cleared by the American regulatory agency in mid-December for combating gonorrhoea. This infection can lead to serious health problems, including the inability to conceive. Scientists believe that targeted use of this new drug will help delay the spread of drug resistance.

Gepotidacin, developed by the drugmaker GlaxoSmithKline, gained clearance in close succession. This treatment, which is additionally indicated for urinary tract infections, was shown in trials to be able to combat superbug versions of the gonorrhoea bacteria.

A Unique Approach to Creation

This new treatment stemmed from a innovative non-profit model for antibiotic development. The charitable organization GARDP collaborated with the drug firm Innoviva to see it through.

“This approval represents a huge turning point in the therapy of superbug gonorrhoea, which previously has been staying ahead of our drug pipeline.”

Clinical Trial Outcomes and Global Access

According to findings published in a major medical journal, the new drug successfully treated more than 90% of genital gonorrhoea infections. This establishes an similar efficacy with the typical regimen, which involves two antibiotics. The trial involved nearly 1,000 participants from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its collaboration, GARDP has the ability to register and commercialise the drug in numerous low-income and middle-income countries.

Doctors on the front lines have voiced hope. Having a one-pill regimen of this kind is hailed as a "game-changer" for managing the epidemic. This is deemed vital to reduce the burden of the disease for patients and to prevent the spread of highly drug-resistant gonorrhoea globally.